HARRISBURG — The fall legislative session is dominated so far by bipartisan calls to combat a deadly opioid abuse epidemic in Pennsylvania. The focus of proposals offered by Gov. Tom Wolf and lawmakers has been on the role of medical professionals in over prescribing narcotic painkillers, and thus, creating a pathway to addiction for drugs like heroin.

The governor urges final action on bills passed by either the House or Senate to put limits on how many painkillers emergency room physicians can prescribe and require doctors to check a new state prescription drug monitoring network when they write a prescription for painkillers.

Getting far less attention is the role of pharmaceutical companies in making addictive painkillers more widely available to patients in recent years.

That may be about to change.

The Associated Press and the Center for Public Integrity, a nonprofit group, have jointly published eye-opening articles looking at a link between the boom in sales of prescription opioids and overdose deaths in recent years. The articles examine how drug manufacturers have spent more than $800 million nationwide on lobbying and campaign contributions between 2006 and 2015 to stop or weaken bills that limit use of opioids. The drug industry has employed more than 1,300 lobbyists to influence the debate at the state and national level on opioid use, according to the articles.

In Pennsylvania, there have been a few voices and proposals targeting drug manufacturers for help in solving the overdose crisis.

During an opioid action rally at the Capitol last week, Rep. Gene DiGirolamo, R-Bensalem, chairman of the House Human Services Committee, called for state attorneys general to file a lawsuit against the drug manufacturers to recover the costs to taxpayers for treating addicts and overdose victims.

“They’ve (drug companies) created a lot of damage,” DiGirolamo said.

He compared the strategy to a multistate lawsuit against the tobacco industry in the 1990s. The lawsuit resulted in a settlement in which tobacco companies make annual payments to states for the costs to medical assistance and other public health programs for treating diseases caused by smoking.

Pennsylvania earmarks these annual payments for a variety of public health programs.

Absent a lawsuit, DiGirolamo has introduced a bill to impose a 10 percent impact fee on sales of opioids in Pennsylvania.

The fee could generate about $75 million annually, he said.

The revenue would go to support a state-run emergency addiction treatment fund and the new state prescription drug monitoring program. A share would go to counties to purchase Narcan for local police and emergency services agencies to attempt to halt overdoses and to support drug and alcohol counseling in county jails and help offset other criminal justice costs.

The Senate Democratic caucus has unveiled an opioid bill package that includes a 10 percent assessment on opioid sales in the state. The revenue under this proposal would go to purchasing naloxone for local law enforcement and supporting addiction prevention and treatment programs.

 

Robert Swift is Harrisburg bureau chief for Times-Shamrock Communications newspapers. Reach him at

rswift@timesshamrock.com.